Please login to the form below
azacitidine
This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.
Givlaari, Rybelsus lead crowded CHMP recommendations
a host of other indications, as well as azacitidine betapharm (azacytidine) and azacitidine Mylan (azacitidine) for the treatment of a number of blood cancers.
Latest news
-
BMS’ oral maintenance therapy boosts survival in AML patients
CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit
-
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial
Regulatory filings expected in first half of 2020. Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory ... The formulation – known as CC-486 – is an
-
Tecentriq’s triple negative breast cancer use among key CHMP nods
The drug gained FDA approval in December 2017. Celgene also received a positive opinion for azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloidleukaemia.
-
Dutch biotech Argenx claims $1.8bn licensing deal with J&J
It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.
-
Pfizer gets first FDA nod for hedgehog inhibitor in AML
And in a bumper day for the therapeutic category, the FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethyelating agent (azacitidine or decitabine) for the exact
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Hydroxychloroquine fails trial as preventative measure against COVID-19
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Regeneron says antibody for COVID-19 could be ready this year
- AstraZeneca forges agreements for equal access to COVID-19 vaccine
- Hydroxychloroquine safety study pulled on data integrity concern
- UCB buys epilepsy firm Engage Tx in $270m deal
- With knowledge and position comes responsibility
- How healthcare comms needs to adapt
- Hydroxychloroquine fails trial as preventative measure against COVID-19
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- AI and genomics: a revolution in drug discovery and development
- ...
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Quick links
Infographics
